Cost-Effectiveness of Ipilimumab in Previously Untreated Patients for Advanced Melanoma in Sweden

Abstract

comparison cohort) who were the same age, race, and gender were identified and matched. A random index date was chosen to minimize selection bias. Patients in both cohorts were required to be at least age 18 years, with continuous medical and pharmacy benefits 1-year pre-and 1-year post-index date. One-to-one propensity score matching (PSM) was used to compare health care costs and utilizations during the follow-up period, between the diseased and comparison cohorts, and adjusted for baseline demographic and clinical characteristics. Results: After risk adjustment by PSM, a total of 19,079 patients in each cohort were matched. Significantly more breast cancer patients had inpatient admissions (23.77% vs. 12.56%, p< 0.0001) and long-term care (7.77% vs. 6.60%, p< 0.0001), other service (99.88% vs. 87.86%, p< 0.0001) and pharmacy visits (77.80% vs. 68.85%, p< 0.0001), compared to those without breast cancer. Breast cancer patients also incurred significantly higher inpatient ($2,141 vs. $1,537, p< 0.0001), long-term care ($7,471 vs. $5,335, p< 0.0001), other service visit ($23,592 vs. $14,780, p< 0.0001) and pharmacy costs ($3,379 vs. $2,787, p< 0.0001) compared to those in the comparison cohort. ConClusions: Breast cancer patients in the Medicaid program incurred substantially higher health care resource utilization and costs compared to those without the disease.

Tumor treating fields and maintenance temozolomide for newly-diagnosed glioblastoma: a cost-effectiveness study

“…Of note, the National Institute for Health and Care Excellence (NICE) in the UK considered such a survival model structure in its decision to license ipilimumab 27,40 . Recent academic research has also relied on this approach to assess ipilimumab and pembrolizumab 41,42 . We also note that the survival model presented here was the basis of successful health technology assessment filings for TTFields in both Japan and Sweden 43,44 .…”

Estimated lifetime survival benefit of tumor treating fields and temozolomide for newly diagnosed glioblastoma patients

“…The National Institute for Health and Care Excellence in the UK considered a similar survival model structure in its decision to license ipilimumab [ 32 , 33 ]. Recent academic research has also relied on this approach to assess ipilimumab and pembrolizumab [ 34 , 35 ].…”